Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.

Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL, Davidson NE.

J Clin Oncol. 1995 May;13(5):1136-43.

PMID:
7738619
2.

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

Noe DA, Rowinsky EK, Shen HS, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff MD, Ettinger DS, et al.

Cancer Res. 1990 Aug 1;50(15):4595-9.

3.

Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.

Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB.

Cancer Res. 1990 Jun 1;50(11):3284-8.

4.

Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin.

Clarke BV, Harwood KV, Donehower R.

J Natl Cancer Inst. 1989 Sep 6;81(17):1331-2. No abstract available.

PMID:
2769786

Supplemental Content

Loading ...
Support Center